The Zacks Analyst Blog Highlights JPMorgan, Johnson & Johnson, Mastercard and Comstock

For Immediate Release

Chicago, IL – August 27 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Johnson & Johnson JNJ, Mastercard Inc. MA and Comstock Holding Companies, Inc. CHCI.

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports for JPMorgan, Johnson & Johnson and Mastercard

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Johnson & Johnson and Mastercard Inc., as well as a micro-cap stock Comstock Holding Companies, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Today's Featured Research Reports

Shares of JPMorgan have gained +12.2% over the year-to-date period against the Zacks Financial - Investment Bank industry’s gain of +13.4%. The company remains well-positioned given the current operating backdrop. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters. Its consumer franchise keeps widening, with U.S. branch builds and Chase digital growth in Europe, while scale, diversified revenues and disciplined balance sheet management drive durable earnings. 

A higher-for-longer rate regime is likely to aid net interest income (NII), and solid markets and investment banking (IB) fees and asset management flows will drive fee income. 

Yet, mortgage trends remain uneven, and expenses are likely to remain high as the bank invests in technology, marketing and growth initiatives. Credit quality is a watch item in a tougher, uncertain macro environment. However, a strong liquidity profile aids enhanced capital returns, with room for selective investments.

(You can read the full research report on JPMorgan here >>>)

Johnson & Johnson’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+33.3% vs. +20.6%). The company’s Innovative Medicine unit is showing a growth trend, despite the loss of exclusivity of Stelara, driven by key products like Darzalex, Tremfya and Erleada and new launches, like Spravato, Carvykti and Tecvayli. The MedTech segment is also showing improved operational growth minus the recent weakness in Abiomed. 

J&J expects sales growth in both segments to be higher in the second half. J&J has also rapidly advanced its pipeline in the past year that will help drive growth through the back half of the decade. The company has “line of sight” to double-digit top-line growth by the end of the decade. 

However, the Stelara patent cliff and lowered expectations for Abiomed in MedTech are key headwinds. The uncertainty around unresolved legal issues lingers.

(You can read the full research report on Johnson & Johnson here >>>)

Shares of Mastercard have outperformed the Zacks Financial Transaction Services industry over the year-to-date period (+5% vs. -1.1%). The company’s scale and brand strength continue to support steady payment network growth, helped by stable consumer and business spending and higher transaction activity. Cross-border and contactless payments remain key long-term growth drivers, while value-added services continue to diversify revenues through cybersecurity, analytics and digital authentication. 

Mastercard’s value-added services and solutions net revenues rose 21% YoY in the first half of 2026. Partnerships and targeted acquisitions extend reach into new payment flows, including stablecoin infrastructure. 

However, rebates and incentives are rising with new and renewed deals. Strategic investment keeps expense growth high, and cross-border activity remains exposed to geopolitical shifts. A premium valuation leaves less room for execution setbacks. As such, we have a Neutral view.

(You can read the full research report on Mastercard here >>>)

Comstock’s shares have outperformed the Zacks Building Products - Home Builders industry over the year-to-date period (+68.3% vs. +0.1%). This microcap company with a market capitalization of $200.70 million saw its first-half 2026 revenues rise 56% year over year, while adjusted EBITDA surged 123%. Managed assets increased 42% to 108, with 92% commercial and 94% residential leasing supporting recurring fees. 

The QTS headquarters lease adds to leasing momentum, while the development pipeline, Institutional Venture Platform and ParkX’s 89% revenue growth expand fee-generating opportunities. Long-term management agreements, supplemental transaction fees and an asset-light, debt-free structure provide a capital-efficient earnings base. 

However, investments in real estate ventures rose to $19 million and cash declined to $25.3 million. Woodland Pointe adds tenant-concentration and development risks, while the Oklahoma data-center venture remains early-stage with limited current revenues. Despite EV/sales trading above its historical median, EV/EBITDA remains below industry levels. 

(You can read the full research report on Comstock here >>>)

Free: Instant Access to Zacks' Market-Crushing Strategies

Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached. 

Get all the details here >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]                                      

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research